Skip to content
DraconiticResearch
Search Sources API
209,932 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Pulmonary Medicine

Burden, factors associated with drug resistance, and treatment outcomes of tuberculosis in prisons in Lima–Callao, Peru, 2024: a multicenter retrospective cohort study

  • Cristian Morán-Mariños1,2
  • Mayra Cordova-Ayllon1
  • Blanca Martinez-Alvarez1
  • Jorge Cuzquen-Salas3
  • Edwin Herrera-Flores4
  • Rosario Guerrero-Yancari5
  • Pamela Almeyda-Zevallos1
  • Beatriz Castro-Cueto6
6 affiliations
  1. 1Unidad de Tuberculosis, Subdirección de Salud Penitenciaria, Instituto Nacional Penitenciario (INPE), Lima, Perú
  2. 2Unidad de Investigación en Bibliometría, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Perú
  3. 3Penal San Juan de Lurigancho, Instituto Nacional Penitenciario (INPE), Lima, Perú
  4. 4Servicio de Neumología, Hospital Nacional Arzobispo Loayza, Lima, Perú
  5. 5Penal Sarita Colonia, Instituto Nacional Penitenciario (INPE), Callao, Perú
  6. 6Penal Miguel Castro Castro, Instituto Nacional Penitenciario (INPE), Lima, Perú
Read full textDOICite

Abstract

Background: Tuberculosis (TB) remains a major public health problem in prisons, where overcrowding, delayed diagnosis, and limited continuity of care may increase disease burden and worsen outcomes. We aimed to estimate the registered TB burden, describe treatment outcomes, and identify factors associated with drug-resistant TB and unfavorable outcomes in prisons in Lima–Callao, Peru, during 2024.

Methods: We conducted a multicenter retrospective cohort study using routinely collected TB surveillance data from 12 prisons. All patients diagnosed with TB who initiated and/or received treatment during 2024 were included. The registered TB burden was estimated as the number of diagnosed and recorded TB cases per 1,000 inmates. Treatment outcome analyses were restricted to patients with recorded programmatic outcomes. Poisson regression with robust variance was used to estimate crude and adjusted relative risks (aRRs) with 95% confidence intervals (CIs).

Results: Overall, 2,060 TB cases were recorded among 33,268 inmates, corresponding to a registered TB burden of 61.9 cases per 1,000 inmates, in the context of a mean overcrowding rate of 160.3%. The registered burden varied across facilities from 0.0 to 122.8 cases per 1,000 inmates, with the highest values observed in Huacho, Lurigancho, and Cañete. The median age was 31 years, and pulmonary TB accounted for 94.0% of cases. Drug-resistant TB was identified in 292 patients (14.2%). In adjusted analyses, drug-resistant TB was associated with younger age and a longer symptom-to-diagnosis interval (aRR per additional day: 1.007; 95% CI: 1.006–1.009). Among patients with documented treatment outcomes (n = 1,347), 1,231 (91.4%) were cured or completed treatment, whereas 116 (8.6%) experienced death, treatment failure, or loss to follow-up. TB/HIV coinfection was associated with unfavorable outcomes (aRR: 4.383; 95% CI: 2.406–7.985).

Conclusions: Prisons in Lima–Callao had a high and heterogeneous registered TB burden. Strengthening systematic screening, timely molecular diagnosis, drug-resistance surveillance, treatment continuity, and structural interventions may reduce missed diagnoses and improve treatment outcomes.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12890-026-04542-2.

Related

  1. Treatment Completion and Associated Factors in Drug-Resistant Tuberculosis, Mbuji-Mayi, Democratic Republic of the Congo: A Retrospective Cohort Study.
    Elvis Badianga Kumbu, Simon Ilunga Kandolo, Michel Kabamba Nzaji
    Infection and drug resistancePeer-reviewedCC BY-NCFull textInfectious diseaseEurope PMCPMC
  2. Factors associated with unsuccessful treatment outcomes among drug-resistant tuberculosis patients in Loreto, Peru, 2015–2023: A retrospective cohort study
    Evelyn Genthell Cordova-Pisco, Tery Vasquez-Hassinger, Estela Huamán-Angeles +2
    PLOS Global Public HealthPeer-reviewedCC BY 4.0Full textInfectious diseasePLOS
  3. Deep learning based detection of active pulmonary tuberculosis from chest radiographs in a retrospective prospective multicenter study
    Abudouresuli Tuersun, Saimaitikari Abudoubari, Jingxu Xu +8
    iSciencePeer-reviewedCC BY-NC-ND 4.0Full textMedical imaging & radiologyCell PressCrossrefPMCEurope PMC
  4. CO062 | REDUCED-DOSE DOACs IN EXTENDED TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (RED-CAT): INTERIM ANALYSIS FROM A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY (COORDINATING CENTER DATA)
    Sara Bergonzi
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  5. Integrated CRISPR-based detection of HIV, tuberculosis, malaria, and resistance-associated variants
    A. S. Jain, A. Si, J. Yap +8
    medRxivPreprintAll rights reservedFull textInfectious diseasemedRxiv

Cite

BibTeXRIS
BibTeX
@article{moranmarinos2026burden,
  title = {{Burden, factors associated with drug resistance, and treatment outcomes of tuberculosis in prisons in Lima–Callao, Peru, 2024: a multicenter retrospective cohort study}},
  author = {Cristian Morán-Mariños and Mayra Cordova-Ayllon and Blanca Martinez-Alvarez and Jorge Cuzquen-Salas and Edwin Herrera-Flores and Rosario Guerrero-Yancari and Pamela Almeyda-Zevallos and Beatriz Castro-Cueto},
  journal = {BMC Pulmonary Medicine},
  year = {2026},
  month = aug,
  doi = {10.1186/s12890-026-04542-2},
  url = {https://doi.org/10.1186/s12890-026-04542-2},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Burden, factors associated with drug resistance, and treatment outcomes of tuberculosis in prisons in Lima–Callao, Peru, 2024: a multicenter retrospective cohort study
AU  - Cristian Morán-Mariños
AU  - Mayra Cordova-Ayllon
AU  - Blanca Martinez-Alvarez
AU  - Jorge Cuzquen-Salas
AU  - Edwin Herrera-Flores
AU  - Rosario Guerrero-Yancari
AU  - Pamela Almeyda-Zevallos
AU  - Beatriz Castro-Cueto
PY  - 2026
DA  - 2026/08/11
JO  - BMC Pulmonary Medicine
DO  - 10.1186/s12890-026-04542-2
UR  - https://doi.org/10.1186/s12890-026-04542-2
AB  - Background: Tuberculosis (TB) remains a major public health problem in prisons, where overcrowding, delayed diagnosis, and limited continuity of care may increase disease burden and worsen outcomes. We aimed to estimate the registered TB burden, describe treatment outcomes, and identify factors associated with drug-resistant TB and unfavorable outcomes in prisons in Lima–Callao, Peru, during 2024.  Methods: We conducted a multicenter retrospective cohort study using routinely collected TB surveillance data from 12 prisons. All patients diagnosed with TB who initiated and/or received treatment during 2024 were included. The registered TB burden was estimated as the number of diagnosed and recorded TB cases per 1,000 inmates. Treatment outcome analyses were restricted to patients with recorded programmatic outcomes. Poisson regression with robust variance was used to estimate crude and adjusted relative risks (aRRs) with 95% confidence intervals (CIs).  Results: Overall, 2,060 TB cases were recorded among 33,268 inmates, corresponding to a registered TB burden of 61.9 cases per 1,000 inmates, in the context of a mean overcrowding rate of 160.3%. The registered burden varied across facilities from 0.0 to 122.8 cases per 1,000 inmates, with the highest values observed in Huacho, Lurigancho, and Cañete. The median age was 31 years, and pulmonary TB accounted for 94.0% of cases. Drug-resistant TB was identified in 292 patients (14.2%). In adjusted analyses, drug-resistant TB was associated with younger age and a longer symptom-to-diagnosis interval (aRR per additional day: 1.007; 95% CI: 1.006–1.009). Among patients with documented treatment outcomes (n = 1,347), 1,231 (91.4%) were cured or completed treatment, whereas 116 (8.6%) experienced death, treatment failure, or loss to follow-up. TB/HIV coinfection was associated with unfavorable outcomes (aRR: 4.383; 95% CI: 2.406–7.985).  Conclusions: Prisons in Lima–Callao had a high and heterogeneous registered TB burden. Strengthening systematic screening, timely molecular diagnosis, drug-resistance surveillance, treatment continuity, and structural interventions may reduce missed diagnoses and improve treatment outcomes.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12890-026-04542-2.
SN  - 1471-2466
ER  -